Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Positive Outlook on DR Horton with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 1, 2024
in Breaking News
0
Real Estate Investment Markets and money
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Raymond James analyst Buck Horne has expressed his optimism for D.R. Horton by maintaining an Outperform rating on the company. In light of recent developments, Horne has decided to revise the price target accordingly. As of February 1, 2024, the adjusted price target stands at $150.

It is worth noting that Horne had previously revised the price target on two occasions. On July 24, 2023, the price target was raised from $140 to $160, reflecting the analyst’s confidence in D.R. Horton’s potential. However, on November 8, 2023, the price target was lowered to $140, indicating a slight adjustment in expectations.

Despite these modifications, Horne’s positive outlook on D.R. Horton’s performance remains unchanged. The adjustments made to the price target simply reflect the analyst’s ongoing assessment of the company’s growth trajectory.

DHI Stock Performance Shines on February 1, 2024: Analysis and Research Recommended for Investors

On February 1, 2024, DHI showcased a strong performance. According to data from CNN Money, DHI was trading near the top of its 52-week range and above its 200-day simple moving average. The stock witnessed an increase of $1.92 since the previous market close, representing a rise of 1.34%. DHI began the trading day at $145.29, opening $2.38 higher than its previous close. These indicators paint a positive picture for DHI’s stock performance on February 1, 2024. However, investors should conduct thorough research and analysis before making any investment decisions.

DHI Stock Performance on February 1, 2024: Decline in Total Revenue, Net Income, and Earnings per Share Raises Concerns for Investors

DHI Stock Performance on February 1, 2024: Revenue and Net Income Decline

On February 1, 2024, DHI stock experienced a decline in both its total revenue and net income compared to the previous year and the previous quarter.

Total revenue for DHI in the past year was reported at $35.46 billion, while in the first quarter of 2024, it stood at $7.73 billion. This represents a 5.92% increase in total revenue compared to the previous year. However, there was a significant decrease of 26.45% in total revenue since the last quarter.

The decline in total revenue can be attributed to various factors, such as changes in market conditions, economic fluctuations, or internal company issues.

Net income, another crucial financial metric, also experienced a decline for DHI. The company reported a net income of $4.75 billion in the past year, which decreased by 18.98% compared to the previous year. In the first quarter of 2024, the net income stood at $947.40 million, representing a significant decline of 37.25% since the last quarter.

Similar to the decline in total revenue, the decrease in net income can be concerning for investors. It indicates that the company’s profitability has been negatively impacted, potentially due to increased expenses, lower sales volumes, or other financial challenges.

Earnings per share (EPS), a key measure of a company’s profitability for each outstanding share of common stock, also experienced a decline for DHI. The EPS was reported at $13.82 in the past year, which decreased by 16.27% compared to the previous year. In the first quarter of 2024, the EPS stood at $2.82, representing a significant decline of 36.57% since the last quarter.

A decline in EPS can be a red flag for investors, as it indicates that the company’s earnings are decreasing on a per-share basis. This could be due to various factors, such as dilution from the issuance of additional shares or a decrease in net income.

Overall, the performance of DHI stock on February 1, 2024, was marked by a decline in total revenue, net income, and earnings per share compared to both the previous year and the previous quarter. Investors should closely monitor the reasons behind these declines and consider the long-term implications for the company’s financial health and stock performance.

Tags: DHI
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Corbus Pharmaceuticals Raises Funds for Clinical Development and Faces Market Fluctuations

Diana Shipping Inc Secures Major Time Charter Contract with Nippon Yusen Kabushiki Kaisha

Energy Company Markets and money

Enterprise Prods Partners Reports Strong FourthQuarter Earnings

Recommended

SKYX Platforms Stock

Marriott Partnership Signals Major Breakthrough for SKYX Platforms

5 months ago
Microsoft Stock

Microsoft’s AI Ambition: A High-Stakes Bet on Future Growth

18 hours ago
Turtle Beach Stock

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

5 months ago
FLO stock news

Cemtrex Shares Surge After Halting Trading Due to Circuit Breaker

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Trending

Rolls Royce Stock
Defense & Aerospace

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

by Dieter Jaworski
February 5, 2026
0

The coming weeks represent a critical juncture for Rolls-Royce. The company is poised to demonstrate whether it...

Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026
CureVac Stock

CureVac Delisted Following BioNTech Acquisition Completion

February 5, 2026
EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification
  • Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report
  • Solana Faces Billions in Potential Token Supply Releases

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com